Jashin J. Wu

University of Miami

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Alexander Egeberg

Bispebjerg Hospital

April W. Armstrong

University of California, Los Angeles

Mina Amin

Los Angeles Medical Center

Erica B. Lee

University of Nebraska Medical Center

Daniel J. No

Kaiser Permanente

Mark Lebwohl

Icahn School of Medicine at Mount Sinai

Jacob P. Thyssen

Frederiksberg Hospital

Stephen K. Tyring

The University of Texas Health Science Center at Houston

Katie R. Pang

Center for Clinical Studies

George Han

Hofstra University

Cooperative Institutions

American Academy of Dermatology

159

Helsinki University Hospital

146

RELX Group (United States)

144

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

139

Technical University of Munich

138

Fundación Instituto Valenciano de Oncología

138

Aristotle University of Thessaloniki

136

Hospital Infantil Universitario Niño Jesús

133

University of California, San Francisco

Harvard University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States

Journal of Psoriasis and Psoriatic Arthritis (2019)

Steven R. Feldman Jashin J. Wu April W. Armstrong Mark Lebwohl Abby Jacobson

Objective: To provide a contemporary comparative assessment of biologic drug costs and cost effectiveness for treating moderate-to-severe psoriasis in the United States. Methods: A literature search was conducted in PubMed on October 4, 2018 with the search terms of “psoriasis,” “biologic,” and “cost” with a filter of publication dates within the last 5 years (2014-2018). Studies included in this review were required to be conducted from a United States perspective. Results: Of the 16 studies retrieved, the costs associated with use of biologic drugs for the treatment of moderate-to-severe psoriasis were relatively high, with some drugs exhibiting sustained lower costs than others. Some comparative findings on the cost-effectiveness of biologic drugs based on the annual treatment cost per Psoriasis Area and Severity Index (PASI) 75 responder concluded that the annual treatment cost was lowest for brodalumab 210 mg at US$48 782; the cost was highest for ustekinumab 45/90 mg (US$87 243), followed by adalimumab 40 mg (US$82 655), ixekizumab 160 mg (US$77 957), and secukinumab 300 mg (US$75 671). The annual treatment cost per PASI 100 responder was also lowest for brodalumab at US$87 585. This pattern remained consistent in other cost studies, with brodalumab being the treatment with the lowest treatment costs when compared to other biologic drugs. Conclusion: Brodalumab was consistently observed to be the least costly treatment option among biologic drugs used to treat moderate-to-severe psoriasis in the United States, which is largely the result of its low-drug cost and high-PASI response rate.

Ixekizumab

Ustekinumab

10.1177/2475530319842174

Cite

Citations (2)

Identification of the multiple chemical constituents from a Chinese medicinal prescription- Erxian Decoction by LC-DAD-ESI-MS

YM Hu Jashin J. Wu Q Liu CW Sze Linsheng Zhong

The 2009 International Conference & Exposition on Traditional Medicine, Guangzhou, China, 9-11 November 2009.

Decoction

Identification

Source

Cite

Citations (0)

Observations on the ongoing shortage of academic dermatologists.

Cutis (2006)

Jashin J. Wu

Economic shortage

Source

Cite

Citations (1)

The risk of COVID-19 in patients with psoriasis: A retrospective cohort study

Journal of the American Academy of Dermatology (2022)

Jashin J. Wu Jeffrey Liu Akshitha Thatiparthi Amylee Martin Alexander Egeberg

Diagnosis code

10.1016/j.jaad.2022.07.040

Cite

Citations (14)

Executive Summary: From the Medical Board of the National Psoriasis Foundation: Perioperative management of immunomodulatory agents in patients with psoriasis and psoriatic arthritis

Journal of the American Academy of Dermatology (2024)

Warren A. James Angela L. Rosenberg Jashin J. Wu Sylvia Hsu April W. Armstrong

10.1016/j.jaad.2024.03.008

Cite

Citations (4)

European trends in the frequency of original research in acne vulgaris, rosacea, dermatitis, psoriasis, skin cancer, and skin infections, 1970-2010

Dermatology Online Journal (2015)

Young Mee Choi Jaspreet K Garcha Jashin J. Wu

We analyzed trends in the frequency of original publications into common dermatologic topics in two premier European journals, the British Journal of Dermatology and the Journal of the European Academy of Dermatology and Venereology. Most notably, we found that psoriasis publications peaked around the mid-to-late 1980's as well as demonstrated an upward trend since the 21st century. Skin cancer research witnessed a gradual increase in the frequency of publications since 1970. These findings were consistent with a prior study analyzing trends in two American dermatology journals. We attempted to analyze these results from a historical perspective as well as provide an outlook on the future of research into these common dermatologic topics.

10.5070/d3214026281

Cite

Citations (0)

Atopic dermatitis on TikTok™: a cross-sectional study

Clinical and Experimental Dermatology (2022)

Aislyn Oulee Mirjana G. Ivanic Alexandra Norden Sogol Stephanie Javadi Jashin J. Wu

Cross-sectional study

10.1111/ced.15322

Cite

Citations (6)

Translating the 2020 AAD-NPF Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologics to Clinical Practice

Cutis (2021)

Vipawee S. Chat S. K. Uppal Donovan G. Kearns George Han Jashin J. Wu

In 2020, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a set of guidelines for the management of psoriasis in adults with systemic nonbiologic therapies, including acitretin, apremilast, cyclosporine, fumaric acid esters, methotrexate, and tofacitinib. This review addresses dosing, efficacy, toxicity, drug-related interactions, and contraindications alongside evidence-based treatment recommendations for each systemic therapy. Important considerations for treatment such as drug selection, initiation of therapy, drug monitoring, and patient management also are discussed. Physicians are encouraged to use these recommendations to guide treatments based on individual patient needs and disease characteristics.

Acitretin

Apremilast

Systemic therapy

10.12788/cutis.0177

Cite

Citations (3)

Cutaneous metastasis to the chest wall from prostate cancer

Journal of the American Academy of Dermatology (2004)

Jashin J. Wu Katie R. Pang David B. Huang Stephen K. Tyring

Pagetoid

10.1016/j.jaad.2003.10.436

Cite

Citations (0)

A reply to: ‘Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials'

British Journal of Dermatology (2017)

M. Amin Daniel J. No Jashin J. Wu

We read with interest the recent article by Rungapiromnan et al. that utilized a meta-analysis to compile data from 38 randomized controlled trials (RCTs) to determine if there is an association between biologic therapies and major adverse cardiovascular events (MACEs) in patients with plaque psoriasis. In the current study, only 10 MACEs were reported over nine of the RCTs examined. The reported absolute values of the Peto odds ratios are worthy of attention. This article is protected by copyright. All rights reserved.

10.1111/bjd.15620

Cite

Citations (1)